Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolensa vs Ilevro for Ocular Inflammation in Cataract Surgery
NCT03886779Phase 4
Key facts
- Status
- Completed
- Start
- Oct 2013
- Primary completion
- Feb 2017
- Sponsor
- Silverstein Eye Centers
- Modality
- Small Molecules
- Drugs
- bromfenac sodium
- Conditions
- ocular inflammation
01
Overview
Phase 4, randomised, double-blind trial of bromfenac sodium in ocular inflammation (2 arms), sponsored by Silverstein Eye Centers. Primary endpoint: Summed Ocular Inflammation Score. Started Oct 2013; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Prolensa
Bromfenac 0.07% QD + pulse dose
Ilevro
Nepafenac 0.3% QD + pulse dose
03
Who it enrols
Adult patients scheduled for unilateral cataract surgery with BCVA 20/200 or better and IOP 5-22 mmHg, excluding those with active inflammation, corneal pathology, or recent use of NSAIDs/steroids.
04
Endpoints
Primary
Summed Ocular Inflammation Score
Secondary
Adverse Events
Slit Lamp Biomicroscopy
Intraocular Pressure
Funduscopic Examination (Dilated)
Beyond the preview
Go deeper on NCT03886779.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03886779.